FDA Approves Janssen’s Sylvant For Rare Castleman’s Disease

The Food and Drug Administration April 23 approved Sylvant (siltuximab) to treat patients with multicentric Castleman’s disease (MCD), a rare disorder similar to lymphoma (cancer of the lymph nodes).

MCD causes an abnormal overgrowth of immune cells in lymph nodes and related tissues, the agency said. The disease usually affects adults who often suffer from fever, night sweats, weight loss and weakness or fatigue because their body’s immune system is weakened and cannot fight infections.

Sylvant, which is marketed by Janssen Biotech Inc., is an injection that works by blocking a protein that stimulates abnormal growth of immune cells, the ...